Therapeutic Drug Monitoring in IBD: Prospective Promise Unfulfilled

[1]  P. Higgins,et al.  Machine Learning Algorithms for Objective Remission and Clinical Outcomes with Thiopurines , 2017, Journal of Crohn's & colitis.

[2]  M. Regueiro,et al.  Silent Crohn's Disease Predicts Increased Bowel Damage During Multiyear Follow-up: The Consequences of Under-reporting Active Inflammation , 2016, Inflammatory bowel diseases.

[3]  D. Franchimont,et al.  Drug-concentration versus symptom-driven dose adaptation of Infliximab in patients with active Crohn's disease: a prospective, randomised, multicentre trial (Tailorix) , 2016 .

[4]  M. Silverberg,et al.  Higher Adalimumab Drug Levels are Associated with Mucosal Healing in Patients with Crohn's Disease. , 2016, Journal of Crohn's & colitis.

[5]  J. Colombel,et al.  Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management , 2016, Clinical and Translational Gastroenterology.

[6]  K. Van Steen,et al.  Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. , 2015, Gastroenterology.

[7]  M. Barclay,et al.  Therapeutic drug monitoring in rheumatic diseases: utile or futile? , 2014, Rheumatology.

[8]  S. Vermeire,et al.  Therapeutic Drug Monitoring in Inflammatory Bowel Disease: Current State and Future Perspectives , 2014, Current Gastroenterology Reports.

[9]  Christopher F. Martin,et al.  Randomised clinical trial: individualised vs. weight‐based dosing of azathioprine in Crohn's disease , 2014, Alimentary pharmacology & therapeutics.

[10]  J. Lund,et al.  Patterns of 6-mercaptopurine and azathioprine maintenance therapy among a cohort of commercially insured individuals diagnosed with Crohn’s disease in the United States , 2013, Clinical epidemiology.

[11]  P. Rutgeerts,et al.  Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient , 2013, The American Journal of Gastroenterology.

[12]  S. Saini,et al.  Cost utility of inflammation-targeted therapy for patients with ulcerative colitis. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[13]  F. Casellas,et al.  Thiopurine methyl‐transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine‐treated inflammatory bowel disease patients , 2011, Alimentary pharmacology & therapeutics.

[14]  Sijian Wang,et al.  Algorithms outperform metabolite tests in predicting response of patients with inflammatory bowel disease to thiopurines. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[15]  V. Armstrong,et al.  6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. , 2007, Clinical chemistry.

[16]  G. Fick,et al.  Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. , 1995, Annals of internal medicine.